Pharma finds a way to gain weight

If 2023’s first quarter painted a somewhat dispiriting picture for biopharma share price performance the second has brought better news. One major factor lies behind the enthusiasm: resurgence in the promise of treatments for obesity, which have resulted in the valuations of Lilly and Novo Nordisk putting on a joint $149bn so far this year.